Atrial Fibrillation Ablation and Autonomic Modulation Via Thorascopic Surgery
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.
Also called NCT01091389
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 240 participants
- Sponsor
- Registry
-
NCT01091389
-
- Other papers using this trial's data
- Clinical, histologic, and molecular associations of early and late recurrence after thoracoscopic ablation for atrial fibrillation
- Does left atrial epicardial conduction time reflect atrial fibrosis and the risk of atrial fibrillation recurrence after thoracoscopic ablation? Post hoc analysis of the AFACT trial
- Ganglion Plexus Ablation in Advanced Atrial Fibrillation: The AFACT Study
- Reduced left atrial cardiomyocyte PITX2 and elevated circulating BMP10 predict atrial fibrillation after ablation
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT01091389. Randomized; single masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2015-02-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Atrial Fibrillation Ablation and Autonomic Modulation Via Thorascopic Surgery
- Acronym
- AFACT
- Condition
- Atrial Fibrillation
- Intervention (Procedure)
- Totally Thoracoscopic PV isolation
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Collaborator
- Netherlands Heart Foundation
Record details
- Record id
cardio:ct-nct01091389- Content hash
869bf106c905640177f3d25bad86563e5a8a20b6f5a3933a05dfd5d3ccd8f7c8